Violaine Havelange

Liege, WAL, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Journal: Haematologica

Published: April 23, 2026

Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025.

Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 31, 2025

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib - final 6-year results from a Belgian registry.

Journal: Hematology (Amsterdam, Netherlands)

Published: August 14, 2025

MiR-92a-1-5p contributes to cellular proliferation and survival in chronic myeloid leukemia and its inhibition enhances imatinib efficacy.

MiR-92a-1-5p contributes to cellular proliferation and survival in chronic myeloid leukemia and its inhibition enhances imatinib efficacy.

Journal: Non-coding RNA research

Published: November 27, 2024

Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest?

Metabolic dysfunction-associated steatotic liver disease : the tree that hides the forest?

Journal: Acta gastro-enterologica Belgica

Published: August 30, 2024

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.

Journal: Blood advances

Published: August 12, 2024

Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.

Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.

Journal: Acta gastro-enterologica Belgica

Published: October 10, 2023

Recent advances in therapies for primary myelofibrosis.

Recent advances in therapies for primary myelofibrosis.

Journal: Faculty reviews

Published: September 29, 2023

Jaundice with severe leucocytosis.

Jaundice with severe leucocytosis.

Journal: Journal of hepatology

Published: September 26, 2023

Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia.

Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia.

Journal: Haematologica

Published: August 25, 2023

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?

Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?

Journal: American journal of hematology

Published: July 31, 2023

Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss.

Gut microbiota alterations induced by intensive chemotherapy in acute myeloid leukaemia patients are associated with gut barrier dysfunction and body weight loss.

Journal: Clinical nutrition (Edinburgh, Scotland)

Published: June 11, 2023

Showing 1-12 of 47

Last Updated: 09/26/2026